J
Jens Pohlmann
Researcher at Bayer Corporation
Publications - 49
Citations - 2114
Jens Pohlmann is an academic researcher from Bayer Corporation. The author has contributed to research in topics: Factor Xa Inhibitor & Prodrug. The author has an hindex of 11, co-authored 49 publications receiving 1867 citations. Previous affiliations of Jens Pohlmann include Bayer HealthCare Pharmaceuticals & University of Basel.
Papers
More filters
Journal ArticleDOI
In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939—an oral, direct Factor Xa inhibitor
Elisabeth Perzborn,Strassburger J,Wilmen A,Jens Pohlmann,Susanne Roehrig,Schlemmer Kh,Alexander Straub +6 more
TL;DR: BAY 59‐7939 inhibited endogenous FXa more potently in human and rabbit plasma than rat plasma, correlating with the 14‐fold lower IC50 ofFXa inhibition in rabbit compared with rat plasma; this may suggest a correlation between FXa inhibition and antithrombotic activity.
Journal ArticleDOI
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor.
Susanne Roehrig,Alexander Straub,Jens Pohlmann,Thomas Lampe,Josef Pernerstorfer,Karl-Heinz Schlemmer,Peter Reinemer,Elisabeth Perzborn +7 more
TL;DR: This work has identified oxazolidinone derivatives as a new class of potent FXa inhibitors and identified BAY 59-7939 (5), a highly potent and selective, direct FXa inhibitor with excellent in vivo antithrombotic activity.
Journal ArticleDOI
The Novel Microtubule-Destabilizing Drug BAL27862 Binds to the Colchicine Site of Tubulin with Distinct Effects on Microtubule Organization.
Andrea E. Prota,Franck Danel,Felix Bachmann,Katja Bargsten,Rubén M. Buey,Jens Pohlmann,Stefan Reinelt,Heidi Lane,Michel O. Steinmetz +8 more
TL;DR: Comparisons of the effects of BAL27862 and colchicine on the microtubule mitotic spindle and in tubulin protease-protection experiments suggest different outcomes of tubulin binding.
Journal ArticleDOI
Identification and Characterization of the First Class of Potent Bacterial Acetyl-CoA Carboxylase Inhibitors with Antibacterial Activity *
Christoph Freiberg,Nina A. Brunner,Guido Schiffer,Thomas Lampe,Jens Pohlmann,Michael Brands,Martin Raabe,Dieter Habich,Karl Ziegelbauer +8 more
TL;DR: It is demonstrated that pseudopeptide pyrrolidine dione antibiotics such as moiramide B inhibit the Escherichia coli enzyme at nanomolar concentrations, and the natural product moIRamide B and synthetic analogues show broad-spectrum antibacterial activity.
Journal ArticleDOI
Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.
Don Benjamin,Dimitri Robay,Sravanth K. Hindupur,Jens Pohlmann,Marco Colombi,Mahmoud Y. M. El-Shemerly,Sauveur Michel Maira,Christoph Moroni,Heidi Lane,Michael N. Hall +9 more
TL;DR: It is reported that syrosingopine, an anti-hypertensive drug, is a dual MCT1 and MCT4 inhibitor that prevents lactate and H+ efflux and is a potential cancer therapy.